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ABSTRAK
Latar belakang: nefritis lupus (NL) proliferatif memiliki prevalensi yang lebih tinggi dan prognosis yang lebih 
buruk dibandingkan NL non-proliferatif. Pemeriksaan histopatologi memegang peranan penting dalam diagnosis 
dan terapi NL proliferatif, namun terdapat beberapa kendala dalam pelaksanaannya. Sistem skor NL proliferatif 
diperlukan untuk membantu diagnosis NL proliferatif terutama pada kondisi biopsi ginjal tidak dapat dilakukan. 
Tujuan penelitian adalah menetapkan sistem skor diagnosis NL proliferatif berdasarkan determinan hipertensi, 
proteinuria, hematuria, eGFR, kadar anti-dsDNA, dan C3. Metode: penelitian diagnostik dengan desain potong-
lintang terhadap 113 pasien NL yang terbukti dari pemeriksaan Patologi Anatomik di RSCM sejak Januari 2007 
hingga Juni 2017 dengan metode total sampling. Data yang digunakan adalah data sekunder. Analisis data 
dilakukan dengan program statistik SPSS Statistics 20.0 untuk analisis univariat, bivariat, multivariat, Receiving 
Characteristics Operator, serta analisis bootstrapping pada Kalibrasi Hosmer-Lemeshow.Hasil: sebanyak 191 
subjek dianalisis untuk proporsi NL proliferatif, didapatkan proporsi NL proliferatif pada pasien NL yang terbukti 
dari biopsi ginjal di RSCM sebesar 74,8%. Sebanyak 113 subjek dianalisis untuk mendapatkan determinan NL 
proliferatif. Pada analisis multivariat, hipertensi (OR= 3,39; 95%IK 1,30-8,84), eGFR <60ml/min/1,73m2 (OR= 
9,095; 95%IK 1,11-74,68), dan penurunan kadar C3 (OR= 3,97; 95%IK 1,41-11,17) merupakan determinan NL 
proliferatif. Hipertensi, eGFR <60ml/min/1,73m2, penurunan kadar C3, dan hematuria, menjadi bagian sistem 
skor diagnosis NL proliferatif. Pada kurva ROC didapatkan AUC sebesar 80,4% (95% IK 71,9-89), dengan titik 
potong skor 3. Kesimpulan: proporsi NL proliferatif pada pasien NL yang terbukti dari biopsi ginjal di RSCM 
adalah 74,8%. Komponen sistem skor diagnosis NL proliferatif terdiri dari hipertensi, eGFR <60ml/menit/1.73m2, 
penurunan kadar C3, dan hematuria.
Kata kunci: determinan, nefritis lupus proliferatif, sistem skor, LES, klinikopatologi.
ABSTRACT
Background: proliferative lupus nephritis (LN) has higher prevalence and worse prognosis than non-
proliferative LN. Renal biopsy plays an important role in diagnosis and therapy of LN, but there are some obstacles 
in its implementation. A diagnostic scoring system for proliferative LN is necessary, especially for cases in which 
renal biopsy cannot be performed. This study aimed to develop a diagnostic scoring system of proliferative LN based 
on its diagnostic determinants including hypertension, proteinuria, hematuria, eGFR, anti-dsDNA antibody, and 
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C3 levels. Methods: a cross-sectional study with total sampling method was conducted. Our subjects were adult 
LN patients who underwent renal biopsy in Cipto Mangunkusumo Hospital between January 2007 and June 2017. 
Results: from a total of 191 subjects with biopsy-proven LN in this study, we found a proportion of proliferative 
LN of 74.8%. There were 113 subjects included for analysis of proliferative LN determinants. The multivariate 
analysis demonstrated that determinants for proliferative LN were hypertension (OR 3.39; 95% CI 1.30-8.84), 
eGFR <60ml/min/1.73m2 (OR 9.095; 95% CI 1.11-74.68), and low C3 levels (OR 3.97; 95% CI 1.41-11.17). After 
further analysis, we found that hypertension, eGFR <60ml/min/1.73m2, low C3 levels, and hematuria were essential 
components of the diagnostic scoring system on proliferative LN. The scoring system was tested with ROC curve 
and an AUC of 80.4% was obtained (95% CI 71.9-89). Conclusion: the proportion of proliferative LN in biopsy-
proven LN patients of Cipto Mangunkusumo Hospital is 74.8%. Components of scoring system for proliferative 
LN consist of hypertension, eGFR <60ml/min/1.73m2, low C3 levels, and hematuria.
Keywords: determinants, proliferative lupus nephritis, scoring system, SLE, clinicopathology.
INTRODUCTION
Systemic Lupus Erythematosus (SLE) is one 
of systemic autoimmune diseases commonly 
found in women at reproductive age. One of the 
clinical manifestations in SLE is renal damage, 
which is known as lupus nephritis (LN). In 
the natural course of the disease, LN occurs in 
40-60% patients.1,2 The cumulative incidence 
of LN is the highest among Asian with higher 
prevalence of proliferative compared to non-
proliferative LN.2-8 Proliferative lupus nephritis 
(LN) has worse prognosis than non-proliferative 
LN, either regarding morbidity or mortality.5,9-11 
However, with appropriate management, the 
prognosis may improve significantly in patients 
who have achieve remission.12
To achieve remission, earlier diagnosis of 
LN and appropriate treatment play an essential 
roles. However, it is not easy to establish early 
diagnosis of proliferative LN based on clinical 
and laboratory features since there are various 
clinical manifestations of LN. Until now, the 
histopathological examination (renal biopsy) is 
still the gold standard for diagnosing LN as well 
as for principles of LN treatment.1,4,5,11
Challenges in Indonesia include uneven 
distribution of facilities for renal biopsy. 
Moreover, there are also some conditions, which 
are the contraindications for performing renal 
biopsy. Therefore, it is necessary to have a tool 
that can be used practically both in clinical and 
laboratory setting to diagnose proliferative LN. 
Some parameters have been previously estimated 
to have some capacity in predicting histological 
class of LN and can differentiate proliferative 
from non-proliferative LN. Those parameters are 
hypertension, degree of proteinuria, hematuria, 
eGFR, anti-dsDNA and low C3 levels.
There have been extensive studies discussing 
clinicopathology of LN, however, no study has 
been specifically designed to develop a scoring 
system for proliferative LN based on clinical 
and laboratory parameters.1,5-8 In our study, we 
attempted to develop a scoring system to assist 
the diagnosis of proliferative LN based on 
clinical and laboratory parameters, particularly 
when the renal biopsy cannot be performed.
METHODS
The present study was a diagnostic study 
with a cross-sectional design in LN subjects who 
underwent renal biopsy in Cipto Mangunkusumo 
Hospital between January 2007 and June 2017. 
The data used were secondary data obtained 
from patient medical records, data from the 
Division of Nephrology and Hypertension and 
data of Pathology Anatomy Department at 
Cipto Mangunkusumo National Central General 
Hospital. The inclusion criteria in our study were 
patients with biopsy-proven LN and aged over 18 
years (adult patients); while the exclusion criteria 
of the present study were incomplete medical 
records. Samples were obtained by total sampling. 
This study has been approved by the ethics 
committee of Faculty of Medicine Universitas 
Indonesia on May 29th, 2017, with a reference 
number 493/UN2.F1/ETIK/2017.
When the study criteria were fulfilled, 
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Anatomical Pathology slides would be re-read 
by a Pathology Anatomy specialist and data were 
documented regarding hypertension, proteinuria, 
hematuria, creatinine level and eGFR as well 
as anti-dsDNA and C3 levels. Hypertension 
was defined as a systolic blood pressure (SBP) 
of ≥140 mm Hg and diastolic blood pressure 
(DBP) of (TDD) ≥90 mmHg according to JNC 
7 classification or the patient had been diagnosed 
with hypertension previously. Proteinuria was 
measured by calculating the level of protein 
in urine quantitatively within 24 hours (mg/24 
hours). Hematuria was defined by the presence 
of >5 red blood cells per high power field (HPF) 
in urine sediment and by excluding the presence 
of urinary stone, infection and other causes.
Estimated Glomerular Filtration Rate (eGFR) 
was calculated based on the CKD-EPI formula. 
The level of anti-dsDNA was measured by using 
ELISA method. C3 was defined as low when it 
was <90 mg/dL. Data analysis was performed 
using a SPSS statistic software program version 
20.0 for univariate, bivariate and multivariate 
analysis, Receiving Characteristics Operator, 
as well as bootstrapping analysis in Hosmer-
Lemeshow calibration.
RESULTS
There were 191 subjects aged >18 years with 
biopsy-proven LN who had undergone renal 
biopsy at Cipto Mangunkusumo National Central 
General Hospital within the period of January 
2007 to June 2017. The proportion of proliferative 
LN in those 191 subjects who had been confirmed 
with LN on their renal biopsies was 74.8% 
(95%CI= 68.6-80.96%). There were 78 subjects 
that had been excluded from the study due to 
incomplete data. As many as 113 patients were 
included in data analysis. Basic characteristics of 
all study subjects can be seen in Table 1.
Table 1. Basic characteristics of study subjects
Subject characteristics Total 
Sex, n (%) 
 - Male 7 (6.2)
 - Female 106 (93.8)
Age, median (range, years) 27 (18-56)
Duration of SLE,  
median (range, months) 9 (0-216)
Table 1. Basic characteristics of study subjects
Subject characteristics Total 
Organ involvement, n (%)
 - Neurologic 10 (10.8)
 - Mucocutaneous 61 (66.3)
 - Hematological 48 (50)
 - Musculoskeletal 68 (73.9)
 - Serositis 25 (26.9)
Therapy, n (%)
 - Not available 7 (6.2)
 - Only steroids 24 (21.2)
 - Steroids and immunosuppresants 82 (72.6)
Hypertension, n (%)
 - No hypertension 43 (38.05)
 - Hypertension 70 (61.95)
Pyuria (n=112), n (%)
 - No pyuria 60 (53.6)
 - Pyuria 52 (46.4)
Hematuria, n (%)
 - No hematuria 32 (28.3)
 - Hematuria 81 (71.7)
Cellular cylinders (n=111), n (%) 
 - No cellular cylinders 70 (61.9)
 - Cellular cylinders 41 (36.3)




Creatinine level, median (mg/dL) 0.7 (0.3-7.3)
eGFR, n (%) 
 - >60 ml/minute/1.73 m2 85 (75.2)
 - <60 ml/minute/1.73 m2 28 (24.8)
 - Median (range, ml/minute/1.73m2) 108.95  (7.2-172)
Albumin level, median (range, g/dL) 2.54 (0.8-4.69)
Anti-dsDNA level, median (range, U/ml) 397.25  (1.5-5510.4)
C3 level, n (%)
 - Normal 25 (22.1)
 - Low 88 (77.9)
 - Median (range, mg/dL) 55.6 (0.9-154)
 C4 level, n (%) 
 - Normal 60 (53.1)
 - Low 51 (45.1)
 - Median (range, mg/dL) 11 (0-51)
Lupus Nephritis Classification (n=113)
 - LN  class I 3 (2.7)
 - LN class II 15 (13.3)
 - LN class III 21 (18.6)
 - LN class IV 50 (44.2)
 - LN  class V 13 (11.5)
 - LN class V+III 1 (0.9)
 - LN class V+IV 10 (8.8)
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On bivariate analysis, we found that the 
determinants, which had significant correlation 
with proliferative LN were hypertension 
(p=0.002), hematuria (p=0.004), eGFR <60 ml/
minute/1.73 m2 (p=0.001), anti-dsDNA (p=0.027) 
and C3 level (p=0.002). Those five variables 
together with the quantitative urine protein 
which had p<0.25 (p=0.181) were included in the 
multivariate analysis as shown in Table 2.
The development of scoring system for 
diagnosing proliferative a LN was carried 
out by calculating B coefficient and standard 
error, which resulted in a diagnostic scoring for 
proliferative LN based on clinical and laboratory 
parameters (Table 3). The scoring system was 
tested on ROC curve (Figure 1) and an AUC of 
0.804 (95%CI 0.709-0.89) was found.
From the curve, we obtained the intersection 
of sensitivity and specificity curve as well as the 
cut-off point for diagnosis (Figure 2).
Based on tables and cut-off point curves 
of sensitivity, specificity with total score of 
diagnosis, we found that the best cut-off point to 
estimate the diagnosis of proliferative LN was 
Table 2. Multivariate analysis on determinants associated with proliferative LN
Variables P value Odd Ratio (OR) 95% CI
Stage 1 C3 level 0.061 2.910 0.95-8.88
eGFR 0.074 7.011 0.83-59.18
Hypertension 0.016 3.308 1.25-8.88
Hematuria 0.150 2.086 0.7-3.00
Quantitative urine protein 0.699 1.000 0.86-3.59
anti-dsDNA 0.420 1.000 0.99-1.00
Stage 2 C3 level 0.058 2.942 0.96-8.98
eGFR 0.074 6.990 0.83-58.85
Hypertension 0.016 3.318 1.25-8.80
Hematuria 0.139 2.125 0.78-5.77
anti-dsDNA 0.430 1 0.99-1.00
Stage 3 C3 level 0.021 3.481 1.20-10.031
eGFR 0.068 7.221 0.87-60.2
Hypertension 0.015 3.337 1.26-8.82
Hematuria 0.137 2.117 0.79-5.69
Stage 4 C3 level 0.009 3.972 1.41-11.17
eGFR 0.040 9.095 1.108-74.68
Hypertension 0.013 3.389 1.3-8.84
Table 3. Diagnostic scoring for proliferative LN
No Variables Category Score
1 Hypertension Yes 2
No 0
2 eGFR < 60 ml/minute/1.73 m2 1
> 60 ml/minute/1.73 m2 0
3 C3 level Low  C3 level (<90) 2
Normal C3 level (90-180) 0
4 Hematuria Yes 1
No 0
Maximum Total Score 6
Minumum Total Score 0
eGFR, estimated Glomerular Filtration Rate
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3 (three). The score of >3 had a sensitivity of 
65.9%, specificity of 83.8%, positive predictive 
value of 91.5%, and negative predictive value 
of 48.14%. The scoring system had a good 
calibration based on statistical significance 
using Hosmer-Lemeshow test (p>0.05), in 
which the p value =0.157. Following 1000 times 
bootstrappings, the calibration stays good based 
on the statistical significance using Hosmer-
Lemeshow test with p=0.157.
DISCUSSION
In our study, there were 106 female subjects 
out of 113 total subjects (93.8%). The result 
is similar to the results in Himawan study13 
in Indonesia and Wakasugi et al.5 in Japan. In 
those studies, the proportion of female to male 
subjects was 93% and 93.7%, respectively. The 
median age of study subjects was 27 years (with 
a range of 18-56 years). Moreover, the median 
Figure 1. ROC curve
Figure 2. The intersection of sensitivity and specificity curve and total score of diagnosis
duration of time since the subjects had their first 
diagnosis of SLE to the moment they underwent 
renal biopsy was 9 months (with a range of 
time of 0 – 216 months) and a mean duration of 
21.16 months (SD 33.91 months). The medians 
and mean for duration of illness in our study are 
almost similar to those in Wakasugi et al.5 and 
LUMINA14 studies. There were various organ 
involvement of SLE patients with LN and in our 
study the most common one was musculoskeletal 
involvement, which is consistent to the findings 
in Mavragani et al.6 and Kalim et al.15 studies. The 
wide range of age and duration of illness as well 
as various organ involvement implicates that the 
outcomes of our study can be implemented in LN 
population with wide range of age and duration 
of SLE as well as a varied manifestations of 
organ involvement in SLE.
The proportion of proliferative LN based on 
ISN/RPS 2003 in our study was 74.8% (95%CI 
of 68.6-80.96). The proportion of proliferative 
LN, which was higher than other classes, had 
also been found in other studies as presented in 
Table 4.
In our study, there were six determinant 
variables that had been studied, i.e. hypertension, 
quantitative urine protein, hematuria, eGFR, 
anti-dsDNA and C3 levels. Among the six 
determinants, there are four variables that 
become the component of proliferative LN 
score, which are hypertension, hematuria, 
eGFR and C3 level. Hypertension occurred 
in 82.9% patients with proliferative LN. In 
the final model of multivariate analysis, we 
found that hypertension was correlated with 
proliferative LN. It is consistent with the results 
of Mavragani et al. study.6 In LN, particularly 
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the proliferative LN, there were loss of nephrons 
and progressive glomerular damage. It can 
exacerbate hemodynamic changes of the kidney 
and increases renal vascular resistance as well 
as reduces renal blood supply, which leads to 
hypertension.16
In our study, there was no significant 
correlation between proteinuria and proliferative 
LN, which is consistent with Hsieh et al.14 
However, it is different from the results of 
Wakasugi et al.5 and Okpechi et al.8 studies. 
There is a significant difference regarding the 
median of proteinuria between our study and 
the Wakasugi et al.5 study; while there is also a 
difference in method of measuring proteinuria 
between our study and the Okpechi et al.8 
study. Proteinuria in SLE patient is generally 
associated with deposition of immune complex 
in subepithelial (particularly in LN class V) and 
subendothelial tissues (particularly in LN class 
IV); therefore, nephrotic-range proteinuria is 
also commonly found in LN class V, which 
is included in the non-proliferative LN. In 
addition to the mechanism of immune complex 
deposition, neprhotic-range proteinuria may 
also occur due to podocyte injuries; therefore, 
it can also be found in LN class II. The findings 
support the hypothesis that the degree of severity 
of LN histopathological findings does not always 
correlate with the degree of proteinuria.17
Hematuria is one of components in 
proliferative LN score. The addition of hematuria 
variable in the scoring system increases the 
discrimination capacity of the system, which 
was evaluated based on AUC in ROC curve. 
In addition to the better score discrimination 
capacity, the pathophysiological (biological 
plausibility) has also become our consideration 
when adding hematuria variable into the 
proliferative LN scoring system. Hematuria in 
LN occurs due to extravasation of red blood 
cells into urine, which is caused by damage 
on glomerular basement membrane (GBM).18 
Several studies have demonstrated that hematuria 
is associated with proliferative LN including 
the Martinez et al.19 and Okpechi et al.8 studies. 
Hematuria is associated with high LN activity 
index and most commonly found in LN class 
III and IV.11,20,21
In LN, inflammation occurs in the kidney 
simultaneously with cytokines and chemokines 
production, which subsequently will stimulate 
leukocyte migration to glomerulus, amplify 
local inflammatory reaction that result in greater 
loss of nephrons and atrophy. It causes reduced 
glomerular filtration rate (GFR).22,23 In addition to 
inflammatory conditions, reduced GFR can also 
be affected by hypertension, which is consistent 
with the presence of renal vasoconstriction and 
the phenomenon of shift to the right of pressure-
natriuresis correlation. GFR and renal plasma 
flow will be reduced.16 In our study eGFR of 
<60 ml/minute/1.73 m2 is a determinant in 
diagnosing proliferative LN, which is consistent 
with the study by Wakasugi et al.5 Another study 
by Vozmediano et al.24 has also found that eGFR 
of <60 ml/minute/1.73m2 was more commonly 
found in patients with LN class III and IV.
In our study, there was no correlation 
between anti-dsDNA level and proliferative 
LN, which is consistent with the Alba et al.25 
study, which showed that the anti-dsDNA was 










II 12.04 15.83 13.5 9.76
III 21.47 63.29 (Class  III/IV) 20.7 12
IV 43.46 20.7 52.4
V 9.42 20.88 14.7 8.53
V+III 0.52 11.2 7.31
V+IV 9.42 8.4 9.76
VI 8.4
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not associated with histological class of NL. The 
Wakasugi et al5 study showed that anti-dsDNA 
was a determinant for diagnosing proliferative 
LN. There are differences in the method of 
evaluating anti-dsDNA between our study and 
the Wakasugi et al.5 study. In SLE patients, 
the titer of their anti-dsDNA did not follow 
the existing pattern, in which was higher when 
there was a flare and was lower without flare. 
The condition is known as serologically-active 
clinically quiescent (SACQ) and clinically-
active serologically quiescent (CASQ).26 Other 
studies also could not demonstrate the correlation 
between anti-dsDNA and the degree of LN 
severity. Anti-dsDNA in serum shows lower 
cross reaction compared to anti-dsDNA found 
in the kidney of LN patients.27 Another study 
suggests that in patients with active severe LN, 
the anti-dsDNA serum levels can be low and 
is assumed to be due to the adsorption of anti-
dsDNA from blood circulation into the kidney; 
therefore, the anti-dsDNA is deposited in the 
kidney. Another explanation would be that in LN, 
there is proteinuria and in such condition anti-
dsDNA is found, which is excreted in the urine. 
Several animal experimental studies have also 
found that there is a disassociation between anti-
dsDNA level and renal disorders.28-30 Low C3 
level is a determinant for diagnosing proliferative 
LN, which is supported by Okpechi et al. and 
Wakasugi et al. studies. Low C3 level is caused 
by increased catabolic rate due to complement 
activation and reduced C3 synthesis, which is 
consistent with the role of complement in the 
pathophysiology of LN. Products of complement 
activation in the circulation will stimulate 
inflammatory cascades that consequently will 
cause tissue damage.26
Our study has developed a scoring system 
as a tool for diagnosing proliferative LN based 
on clinical and laboratory parameters. The 
advantage of developing the scoring system is 
to select LN patients that have high estimation 
value (which are characterized by higher score 
than the cut-off point limit) to experience 
proliferative LN, particularly when renal biopsy 
is not possible.
To our knowledge, there have been many 
studies discussing the clinicopathology of LN; 
however only three studies had demonstrated 
determinant results to estimate LN with 
components of class III/IV with different results 
among those studies. There are some differences 
between our study and previous studies, which 
are: (1) no study has been conducted which 
develop a scoring system for proliferative 
LN; (2) previous study was performed for 
different ethnical background, i.e. the study by 
Wakasugi et al.5 in Japan (Asia), which also 
involved children population; (3) in the study by 
Wakasugi et al.5 the estimation of proliferative 
LN was divided into silent and overt LN and 
there was no score model for overall estimation 
of proliferative LN; (4) Mavragani et al.6 did 
not differentiate specifically the estimation 
for diagnosing proliferative LN and excluded 
the LN mixed class V; (5) in Okpechi et al.8 
study, LN mixed class V (V+II) was included in 
proliferative LN and the proteinuria parameter 
was measured by dipstick test; while the gold 
standard of evaluating proteinuria should be 
performed by measuring 24-hour proteinuria.
Our scoring system is labeled as the Diagnostic 
Score for Proliferative LN. The score system has 
good calibration and discrimination. When an 
analysis was performed on probability of total 
score in study subjects against the proliferative 
LN, we could see that the higher the total score, 
the greater the probability to have proliferative 
LN. In patients with total score of >3, e.g. those 
with total score of 4 had 80.77% probability; 
those with total score of 5 had 89.75% probability 
and those with score of 6 had 94.81% probability. 
Following the analysis for probability, sensitivity 
and specificity tests was performed for score 
of >3 against proliferative LN. We found that 
the sensitivity for the score was 65.9%, the 
specificity was 83.9%, the positive predictive 
value (PPV) was 91.5% and negative predictive 
value (NPV) was 48.2%. It indicates that score 
of >3 are specific to determine that the subject 
should be included in proliferative LN. It is also 
supported by the high PPV, although the score 
may not exclude the proliferative LN (65.9% 
sensitivity and 48.2% NPV).
Our study has collected samples in a 
relatively long period, i.e. 10 years and it is 
the first study demonstrating the proportion 
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of proliferative LN in adult LN patients in 
Indonesia with classification of NL class 
based on ISN/RPS 2003. The development of 
diagnostic scoring system for proliferative LN 
is the first attempt that has ever been done. The 
limitation of our study is that many patients 
had received corticosteroid treatment and/or 
immunosuppressant when the renal biopsy was 
performed. However, it was inevitable and had 
also been found in previous studies. Our study 
also used secondary data; therefore, incomplete 
medical records made subjects became excluded. 
However, in the overall analysis, which is 
accompanied with missing data, there was no 
difference in basic subject characteristics.
CONCLUSION
The proportion of proliferative LN in patients 
who have undergone renal biopsy is 74.8%. 
Components of scoring system for proliferative 
LN consist of hypertension, eGFR <60ml/
min/1.73m2, low C3 levels, and hematuria
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